FDA reversal on Moderna’s mRNA-1010 can transform the seasonal influenza vaccines market: GlobalData EP News Bureau Feb 24, 2026 GlobalData highlights that the FDA’s review of Moderna’s mRNA-1010, with a 05 August 2026 PDUFA date, could introduce the first…
FDA acceptance of VCTE as trial endpoint can accelerate MASH drug development: GlobalData EP News Bureau Sep 1, 2025 GlobalData notes FDA’s acceptance of VCTE as a surrogate endpoint may reduce reliance on biopsies, ease patient enrolment, and…
AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata with latest… EP News Bureau Aug 11, 2025 Phase III UP-AA trial data show higher response rates than current JAK inhibitors, positioning AbbVie’s upadacitinib as a…
